Prognostic analysis of definitive three-dimensional radiotherapy for non-surgically resectable esophageal squamous cell carcinoma: a multi-center retrospective study (3JECROG R-01)

• DOI: 10.3760/cma.j.issn.1004-4221.2018.11.002
• Publication Date: 2018-11-15
• Authors: Xin Wang; Lan Wang; Junqiang Chen; Wencheng Zhang; Xiaomin Wang; Xiaolin Ge; Wenbin Shen; Miaomiao Hu; Qianqian Yuan; Yonggang Xu; Chongli Hao; Zhiguo Zhou; Shuai Qie; Na Lü; Qingsong Pang; Yidian Zhao; Xinchen Sun; Kaixian Zhang; Gaofeng Li; Ling Li; Xueying Qiao; Miaoling Liu; Yadi Wang; Lei Deng; Wenqing Wang; Nan Bi; Tao Zhang; Wei Deng; Chen Li; Wenjie Ni; Xiao Chang; Weiming Han; Zongmei Zhou; Jun Liang; Qinfu Feng; Lvhua Wang; Dongfu Chen; Jima Ly; Shuchai Zhu; Chun Han; Zefen Xiao
• Keywords: Single Center; Esophageal Neoplasm; T-stage

Objective To evaluate the survival and prognostic factors of esophageal cancer treated with definitive (chemo) radiotherapy by applying novel radiation techniques including three-dimensional conformal (3DCRT) or intensity-modulated (IMRT).

Methods Clinical data 2762 patients non-operated squamous cell carcinoma who underwent from 2002 to 2016 in 10 hospitals were retrospectively analyzed.The also identified analyzed.

Results The median follow-up time was 60.8 months.The 1-, 2-, 3-and 5-year overall (OS) all 71.4%, 48.9%, 39.3%, 30.9%, respectively.The progression-free (PFS) 59.5%, 41.5%, 35.2%, 30%, 23 progression 17.2 months.Multivariate analysis demonstrated that age, primary tumor location, clinical stage, target volume, EQD2 treatment mode independent for OS.Primary volume PFS.

Conclusions In this first large-scale multi-center retrospective China, OS is significantly improved 3DCRT, IMRT combined chemotherapy drugs. However, findings remain be validated prospective trials high-level medical evidence.

Key words: Esophageal neoplasm/radiotherapy; Esophageal neoplasm/chemotherapy; Prognosis